The Effect of Culturally Adapted CBT-based Guided Self Help in Depressed Patients With Myocardial Infarction

Depression Clinical Trial

Official title:

The Effect of Culturally Adapted Cognitive Behaviour Therapy (CaCBT)-Based Guided Self Help in Depressed Patients With Myocardial Infarction. A Randomised Controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04347525
• Other study ID #: CBT Post-MI LHR
• Status: Completed
• Phase: N/A
• Start date: October 22, 2019
• Est. completion date: April 25, 2020

Study information

• Verified date: November 2022
• Source: Peshawar Medical College
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized controlled assessor-blind clinical trial comparing CaCBT based guided self-help (using a manual titled Khushi Aur Khatoon) against treatment as usual (TAU)

Description:

Among patients with heart disease, depression and anxiety disorders are extremely common. After a myocardial infarction (MI), depression tends to persist over the next year. Similarly, among individuals who have significantly elevated anxiety following an episode of acute coronary syndrome, only 50% have a resolution of their anxiety in the year after the event, which suggests that anxiety can remain a chronic problem for many patients. Depression confers a 2-fold increased risk of mortality and adverse cardiac events after MI or heart failure and has been linked to poor outcomes after cardiac surgery.

Cognitive behavioural therapy (CaCBT) is the best-studied form of psychotherapy in patients who have had a myocardial infarction, in reducing depressive symptoms. However, there is a dearth of literature on the use of psycho-social interventions in those with medical problems in low and middle-income countries. This study is planned to explore the effect of culturally adapted Cognitive Behavioural Therapy (CaCBT) based Guided self-help (using the book, Khushi Aur Khatoon) compared with treatment as usual in improving depression in MI patients. Participants visiting the Punjab Institute of Cardiology - Lahore, who meet the entry criteria will be randomly allocated to one of the groups, i.e., CaCBT (Intervention group) or TAU (Control Group) in a 1:1 ratio. after taking written informed consent.

With a 5% significance level and 90% power, it was calculated that 48 subjects per group were required for the trial, with a total number of 96. To accommodate up to 30% of the dropout, the participants plan to recruit 140 participants in the study.

Participants were assessed at baseline and 9-12 weeks (end of therapy) from baseline. The primary outcome measure was the Hospital Anxiety and Depression Scale (HADS). The secondary outcome measures include HADS Anxiety and Depression Subscales; Bradford Somatic Inventory (BSI) and World Health Organization Disability Assessment Schedule (WHO DAS 2.0). The participants also measured satisfaction with the treatment at the end of therapy using a visual analog scale.

The participants followed the CONSORT guidelines for reporting randomized controlled trials. The analyses were carried out on an intention-to-treat basis using SPSS version 25. Comparisons for intention-to-treat analysis participants were included in the groups to which they are randomized regardless of how long or even whether they received the treatment allocated to them or not. Missing values were imputed using the last observation carried forward (LOCF) method. Both Chi-Square and t-tests were used for baseline comparisons. End-of-therapy scores on various outcome measures between the Intervention and the Control groups were compared using an Analysis of Covariance (ANCOVA) to adjust for baseline scores.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 140
• Est. completion date: April 25, 2020
• Est. primary completion date: March 15, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Diagnosis of Myocardial Infarction

• Score 8 or more on HADS

• Fulfilling criteria of Major Depressive Disorder using DSM-V

Exclusion Criteria:

• Participants with use of alcohol or drugs

• Significant cognitive impairment (intellectual disability or dementia)

• Active psychosis

• Participants who have received CBT during the previous 12 months

Related Conditions & MeSH terms

• Depression
• Infarction
• Myocardial Infarction

Intervention

Other:
• CaCBT based guided self help using Khushi aur Khatoon Manual
CaCBT based guided self help using the manual named Khushi Aur Khatoon in the intervention arm

Locations

Country	Name	City	State
Pakistan	Punjab Institute of Cardiology	Lahore	Punjab

Sponsors (2)

Lead Sponsor	Collaborator
Peshawar Medical College	Pakistan Association of Cognitive Therapists

Country where clinical trial is conducted

Pakistan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Hospital Anxiety and Depression Scale-Depression Subscale (HAD-D)	Change in the score of the Hospital Anxiety and Depression Scale (HADS) from baseline to end of therapy. The total score is the sum of the 7 items, ranging from 0-21. A total subscale score of >8 points out of a possible 21 denotes considerable symptoms of depression.	9-12 weeks (end of therapy)
Secondary	Hospital Anxiety and Depression Scale - Anxiety Subscale (HADS-A)	Change in the score of the Hospital Anxiety and Depression Scale, Anxiety subscale (HADS-A) from baseline to end of therapy. The total score is the sum of the 7 items, ranging from 0-21. A total subscale score of >8 points out of a possible 21 denotes considerable symptoms of anxiety.	9-12 weeks (end of therapy)
Secondary	Bradford Somatic Inventory (BSI)	Change in the score of Bradford Somatic Inventory (BSI) from baseline to end of therapy. Respondents rank each feeling item on a 5-point scale ranging from 0 (not at all) to 4 (extremely). Rankings characterize the intensity of distress during the past 7 days. Scores can be summed for each dimension, or calculated into each global index.	9-12 weeks (end of therapy)
Secondary	World Health Organisation Disability Assessment Schedule (WHODAS 2.0)	Change in the score of World Health Organisation Disability Assessment Schedule (WHODAS 2.0) from baseline to end of therapy. The total score for WHODAS ranges from 0-100, where a high score indicates major living limitations.	9-12 weeks (end of therapy)